CN107541515B - siRNA for specifically inhibiting PRV1 gene expression and recombinant vector and application thereof - Google Patents
siRNA for specifically inhibiting PRV1 gene expression and recombinant vector and application thereof Download PDFInfo
- Publication number
- CN107541515B CN107541515B CN201710624257.8A CN201710624257A CN107541515B CN 107541515 B CN107541515 B CN 107541515B CN 201710624257 A CN201710624257 A CN 201710624257A CN 107541515 B CN107541515 B CN 107541515B
- Authority
- CN
- China
- Prior art keywords
- prv1
- sirna
- cells
- taxol
- ovarian cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 108020004459 Small interfering RNA Proteins 0.000 title claims abstract description 56
- 230000014509 gene expression Effects 0.000 title claims abstract description 54
- 101000980845 Homo sapiens CD177 antigen Proteins 0.000 title claims abstract description 51
- 102100024209 CD177 antigen Human genes 0.000 title claims abstract description 40
- 239000013598 vector Substances 0.000 title claims abstract description 29
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 13
- 229930012538 Paclitaxel Natural products 0.000 claims abstract description 80
- 229960001592 paclitaxel Drugs 0.000 claims abstract description 80
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims abstract description 80
- 206010033128 Ovarian cancer Diseases 0.000 claims abstract description 36
- 206010061535 Ovarian neoplasm Diseases 0.000 claims abstract description 36
- 206010059866 Drug resistance Diseases 0.000 claims abstract description 20
- 230000000692 anti-sense effect Effects 0.000 claims abstract description 19
- 239000003814 drug Substances 0.000 claims abstract description 16
- 108091081021 Sense strand Proteins 0.000 claims abstract description 14
- 229940079593 drug Drugs 0.000 claims abstract description 12
- 238000002360 preparation method Methods 0.000 claims description 6
- 239000002773 nucleotide Substances 0.000 claims description 5
- 125000003729 nucleotide group Chemical group 0.000 claims description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 abstract description 86
- 210000004881 tumor cell Anatomy 0.000 abstract description 15
- 108090000623 proteins and genes Proteins 0.000 abstract description 14
- 230000006907 apoptotic process Effects 0.000 abstract description 8
- 238000013508 migration Methods 0.000 abstract description 8
- 230000005012 migration Effects 0.000 abstract description 7
- 108020004999 messenger RNA Proteins 0.000 abstract description 5
- 208000005718 Stomach Neoplasms Diseases 0.000 abstract description 4
- 206010017758 gastric cancer Diseases 0.000 abstract description 4
- 230000009545 invasion Effects 0.000 abstract description 4
- 230000035755 proliferation Effects 0.000 abstract description 4
- 201000011549 stomach cancer Diseases 0.000 abstract description 4
- 206010009944 Colon cancer Diseases 0.000 abstract description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 abstract description 3
- 206010029260 Neuroblastoma Diseases 0.000 abstract description 3
- 102000004169 proteins and genes Human genes 0.000 abstract description 3
- 230000002441 reversible effect Effects 0.000 abstract description 3
- 239000003560 cancer drug Substances 0.000 abstract description 2
- 239000004055 small Interfering RNA Substances 0.000 description 50
- 238000001890 transfection Methods 0.000 description 43
- 239000013612 plasmid Substances 0.000 description 21
- 239000013642 negative control Substances 0.000 description 17
- 230000000694 effects Effects 0.000 description 16
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 12
- 108020004414 DNA Proteins 0.000 description 12
- 238000001514 detection method Methods 0.000 description 12
- 238000000034 method Methods 0.000 description 12
- 238000011160 research Methods 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 230000012292 cell migration Effects 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 7
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 7
- 230000004663 cell proliferation Effects 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 239000012634 fragment Substances 0.000 description 7
- 230000009368 gene silencing by RNA Effects 0.000 description 7
- 230000009471 action Effects 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 230000035945 sensitivity Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 238000001262 western blot Methods 0.000 description 6
- 241000283707 Capra Species 0.000 description 5
- 230000030279 gene silencing Effects 0.000 description 5
- 238000012226 gene silencing method Methods 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 239000008055 phosphate buffer solution Substances 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 4
- 102000003952 Caspase 3 Human genes 0.000 description 4
- 108090000397 Caspase 3 Proteins 0.000 description 4
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 4
- 108091027967 Small hairpin RNA Proteins 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 238000002512 chemotherapy Methods 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 230000008506 pathogenesis Effects 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 238000010839 reverse transcription Methods 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 102000003960 Ligases Human genes 0.000 description 3
- 108090000364 Ligases Proteins 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000004709 cell invasion Effects 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 238000004925 denaturation Methods 0.000 description 3
- 230000036425 denaturation Effects 0.000 description 3
- 238000007865 diluting Methods 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 108010082117 matrigel Proteins 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- 108020005544 Antisense RNA Proteins 0.000 description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 108010042352 Urokinase Plasminogen Activator Receptors Proteins 0.000 description 2
- 102000004504 Urokinase Plasminogen Activator Receptors Human genes 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000003184 complementary RNA Substances 0.000 description 2
- 238000002247 constant time method Methods 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000003448 neutrophilic effect Effects 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 230000000149 penetrating effect Effects 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 239000013600 plasmid vector Substances 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 230000032361 posttranscriptional gene silencing Effects 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 238000006748 scratching Methods 0.000 description 2
- 230000002393 scratching effect Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 101150039504 6 gene Proteins 0.000 description 1
- CZVCGJBESNRLEQ-UHFFFAOYSA-N 7h-purine;pyrimidine Chemical compound C1=CN=CN=C1.C1=NC=C2NC=NC2=N1 CZVCGJBESNRLEQ-UHFFFAOYSA-N 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- 102100027708 Astrotactin-1 Human genes 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 238000007808 Cell invasion assay Methods 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000032027 Essential Thrombocythemia Diseases 0.000 description 1
- 208000009849 Female Genital Neoplasms Diseases 0.000 description 1
- 229940122498 Gene expression inhibitor Drugs 0.000 description 1
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 101000936741 Homo sapiens Astrotactin-1 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 208000008601 Polycythemia Diseases 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- 239000006180 TBST buffer Substances 0.000 description 1
- 244000162450 Taxus cuspidata Species 0.000 description 1
- 235000009065 Taxus cuspidata Nutrition 0.000 description 1
- 208000005485 Thrombocytosis Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 201000003948 acquired polycythemia Diseases 0.000 description 1
- 208000017733 acquired polycythemia vera Diseases 0.000 description 1
- 101150063416 add gene Proteins 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108010078837 aspartyl-glutamyl-valyl-aspartyl-p-nitroanilide Proteins 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 238000002737 cell proliferation kit Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000012938 design process Methods 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 230000001516 effect on protein Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000003209 gene knockout Methods 0.000 description 1
- 230000037440 gene silencing effect Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000036046 immunoreaction Effects 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000010832 independent-sample T-test Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 238000010232 migration assay Methods 0.000 description 1
- 230000001617 migratory effect Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000036457 multidrug resistance Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 238000002135 phase contrast microscopy Methods 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 208000037244 polycythemia vera Diseases 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 239000012474 protein marker Substances 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000009933 reproductive health Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 208000013213 secondary polycythemia Diseases 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 238000010583 slow cooling Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses siRNA for specifically inhibiting PRV1 gene expression, a recombinant vector thereof and application thereof in reversing ovarian cancer taxol resistance, belonging to the technical field of molecular biology and biomedicine. The siRNA comprises a sense strand and an antisense strand, wherein the sense strand: 5'-UUCUUAGGGGUCCAUUGCCGG-3', respectively; antisense strand: 5'-GGCAAUGGACCCCUAAGAACA-3' are provided. The siRNA provided by the invention can specifically and efficiently inhibit the mRNA and protein expression of PRV1 gene in tumor cells, reduce the proliferation of the tumor cells, increase the apoptosis, reduce the migration and invasion capacity of the tumor cells, and effectively reverse the drug resistance of ovarian cancer cells to paclitaxel. The invention also provides application of the siRNA and the recombinant vector thereof in preparing medicines for treating ovarian cancer, gastric cancer, colorectal cancer, neuroblastoma or reversing ovarian cancer drug resistance.
Description
Technical Field
The invention relates to the technical field of molecular biology and biomedicine, in particular to siRNA for specifically inhibiting PRV1 gene expression, a recombinant vector and application thereof.
Background
RNA interference (RNAi) is a widely occurring sequence-specific post-transcriptional gene silencing mechanism in animals and plants. In 1998, Andrew Fire, an American scientist, first found that a mixture of sense and antisense strands (i.e., dsRNA) produced at least 10 times the effect of gene silencing over antisense nucleotides in C.elegans, and induced the same phenomenon in progeny. The mechanism research of RNAi phenomenon shows that trace siRNA can silence a large amount of target RNA through post-transcriptional gene silencing, and the key molecule for efficiently and specifically degrading homologous RNA to cause sequence-specific gene silencing is small double-stranded oligonucleotide with 21-23 bases, also called small interfering RNA (siRNA). Further research shows that the double-stranded RNA shorter than 21bp or longer than 25bp can not effectively start RNAi, and the gene silencing effect is obviously reduced or even eliminated as long as one base is mismatched, so that the specificity of the siRNA effect is fully embodied.
siRNA showing strong gene silencing efficacy has attracted attention as a significant finding in recent biotechnology because it has specificity and high efficiency in blocking gene suppression function of homologous genes and is a powerful tool for gene function studies. siRNA has many incomparable advantages and features over traditional methods. Although there are several methods for inhibiting the expression of specific genes, such as antisense RNA, knock-out (knock-out), etc., siRNA has shown significant advantages over these techniques: it has higher specificity and persistence compared to antisense RNA; compared with complex and time-consuming gene knockout, siRNA is a simpler and more effective means. At present, the method of using siRNA as gene silencing is widely used for the research of malignant tumor mechanisms, the key point of the research is mainly focused on how to improve the gene silencing efficacy, including target gene locus selection, optimization of an introduction system, influence on host cell functions and the like, and the research and development process of tumor specific high-efficiency targeted therapy strategies based on the technology is promoted.
Ovarian cancer is one of the most common gynecological malignant tumors, and the mortality rate of ovarian cancer is the first of all gynecological tumors. The biggest obstacle to ovarian cancer treatment is the development of tumor cell resistance, especially the emergence of multidrug resistance. With the implementation of the combined chemotherapy of the platinum/taxol medicaments, the primary chemotherapy response rate of the ovarian cancer can reach 80%, but most patients relapse within 2-3 years. Even if the ovarian cancer is treated by chemotherapeutics with completely different action mechanisms, the ovarian cancer is resistant, so that the survival rate of the treated tumor cannot be obviously improved. The five-year survival rate of the advanced ovarian cancer always ranges from 20% to 30%. High recurrence rate and high drug resistance rate after recurrence are one of the leading causes of high mortality of ovarian cancer, and the search for a solution to drug resistance in ovarian cancer chemotherapy is an important subject of current tumor research.
The combined application of molecular targeted drugs and chemotherapy is the most promising treatment method for improving the survival rate of malignant tumor patients at present. Research shows that a subgroup of tumor cells, tumor stem-like cells (CSCs), can cause tumor formation and drug resistance, and the drug resistance of the CSCs and the expression of some key genes have obvious correlation. Some CSCs marker molecules and drug resistance related genes are also sequentially found in ovarian cancer cells, and one of the genes of the neutrophil surface molecule PRV1 is. The PRV1 gene belongs to a member of the leukocyte antigen 6 gene superfamily, is usually expressed on the cell membrane of neutrophilic granulocytes, and is originally found to be abnormally increased on the neutrophilic granulocytes of patients with primary thrombocythemia and polycythemia vera, so that the PRV1 gene is used for differential diagnosis of secondary thrombocythemia and secondary polycythemia. However, in later researches, PRV1 in progressive gastric cancer cells is obviously highly expressed, the expression level and clinical prognosis indexes of gastric cancer are obviously related, and the higher the expression level, the worse the prognosis. Recent literature reports that the PRV1 gene is also highly expressed in colorectal cancer, neuroblastoma and ovarian cancer. Meanwhile, the structure of PRV1 is very similar to that of urokinase-type plasminogen activator receptor (uPAR) family members, and the uPAR-type genes are closely related to the adhesion and migration characteristics of cells, and the abnormal adhesion and migration capabilities are the characteristics of tumor cells different from normal cells.
Our previous studies showed that PRV1 was abnormally elevated in the paclitaxel-resistant cell line A2780/Taxol for ovarian cancer, but whether the gene is related to the onset and resistance of ovarian cancer remains to be further studied. Therefore, interference of PRV1 gene expression in the drug-resistant cell strain of ovarian cancer by adopting RNAi technology is an important supplement to the pathogenesis of ovarian cancer and an important exploration and application to the treatment of ovarian cancer and drug resistance thereof.
Disclosure of Invention
The invention aims to provide siRNA for specifically inhibiting PRV1 gene expression, which is used for researching the pathogenesis of ovarian cancer. The invention also aims to provide application of the siRNA in preparing medicaments for treating ovarian cancer and reversing paclitaxel drug resistance.
In order to achieve the purpose, the invention adopts the following technical scheme:
the invention designs and synthesizes 3 pairs of siRNA for specifically inhibiting PRV1 gene expression, and the siRNA is transfected into an ovarian cancer Taxol resistant cell strain A2780/Taxol, and the result shows that S1 has the most obvious interference effect for inhibiting PRV1 gene expression.
The invention provides siRNA (S1) for specifically inhibiting PRV1 gene expression, which comprises a sense strand and an antisense strand,
the sense strand: 5'-UUCUUAGGGGUCCAUUGCCGG-3' (SEQ ID NO. 1);
the antisense strand: 5'-GGCAAUGGACCCCUAAGAACA-3' (SEQ ID NO. 2).
Preferably, the sense and antisense strands are 2 ' -methoxy modified at the 5 ' and 3 ' ends of the 3 bases. The research of the invention proves that the stability of the siRNA (S1) modified by the 2' -methoxy group is increased, the capability of resisting the hydrolysis of ribozyme in vivo can be improved, the immune stimulation reaction is reduced, the action time of siRNA interfering the expression of gene to be reduced is prolonged, and the action has high efficiency and specificity.
The invention provides an RNA interference kit comprising a DNA sequence encoding the siRNA. The kit comprises a DNA plasmid vector cloned with the siRNA, and when the kit is applied, the plasmid vector transcribes and expresses the siRNA in eukaryotic cells, so that the expression of PRV1 gene is silenced.
Preferably, the original vector adopted is a lentiviral vector p L KO.1puro.
The invention also provides a construction method of the recombinant vector, which comprises the following steps:
(1) synthesizing a PRV1-S1 fragment, selecting two restriction enzyme sites of Age I and EcoR I, and designing the shRNA sequence according to the sequence of S1, wherein the sequence is as follows:
sense strand:
5’-CCGGTGTTCTTAGGGGTCCATTGCCGGTTCAAGAGACCGGCAATGGACCCCTAAGAACATTTTTTGGTACC-3’(SEQ ID NO.7)；
antisense strand:
5’-AATTGGTACCAAAAAATGTTCTTAGGGGTCCATTGCCGGTCTCTTGAACCGGCAATGGACCCCTAAGAACA-3’(SEQ ID NO.8)；
(2) annealing to obtain a DNA fragment of PRV 1-S1;
(3) the p L KO.1-PRV1-sh1 recombinant vector was constructed using the lentiviral vector p L KO.1puro.
The siRNA provided by the invention can efficiently and specifically inhibit the expression of PRV1 gene in ovarian cancer cells, reduce cell proliferation, increase apoptosis and reduce cell migration and invasion capacity, so that the siRNA and the recombinant vector serving as PRV1 gene expression inhibitors can be applied to the research of pathogenesis of tumor diseases.
The invention provides application of the siRNA and the recombinant vector in preparation of a PRV1 gene expression inhibitor.
The invention provides application of the siRNA and the recombinant vector in preparing medicines for treating ovarian cancer, gastric cancer, colorectal cancer or neuroblastoma.
The research of the invention shows that after the siRNA is transfected by the paclitaxel resistant strain A2780/Taxol, the sensitivity of the cell strain to paclitaxel is obviously improved, and the reversal index is 12.97, which shows that the siRNA provided by the invention has very obvious reversal effect on the drug resistance of the paclitaxel resistant strain A2780/Taxol, therefore, the siRNA has potential application value on the treatment of reversing the drug resistance of ovarian cancer paclitaxel.
The invention provides application of the siRNA and the recombinant vector in preparation of a medicine for reversing drug resistance of ovarian cancer taxol.
The invention has the following beneficial effects:
the siRNA provided by the invention can specifically and efficiently inhibit the expression of mRNA and protein of PRV1 gene, reduce the proliferation of tumor cells, increase the apoptosis of tumor cells, reduce the migration and invasion capacity of tumor cells, and effectively reverse the drug resistance of ovarian cancer cells to paclitaxel, and has important significance in the study of tumor pathogenesis and the preparation of drugs for tumor treatment and ovarian cancer drug resistance treatment.
Drawings
FIG. 1 shows the detection of PRV1mRNA expression in A2780 cells and A2780/Taxol cells by qRT-PCR, wherein A is A2780 cells and AR is A2780/Taxol cells.
FIG. 2 shows Western Blotting to detect PRV1 protein expression in A2780 cells and A2780/Taxol cells, wherein A is A2780 cells, and AR is A2780/Taxol cells.
FIG. 3 shows the expression of PRV1mRNA in A2780/Taxol cells 48h after transfection with S1, S2, S3 by qRT-PCR.
FIG. 4 shows the expression of PRV1 protein in A2780/Taxol cells after transfection with S1, S2 and S3 for 72h by Western Blotting.
FIG. 5 is a schematic diagram of the p L KO.1-PRV1-sh1 recombinant plasmid and the inserted enzyme cutting sites.
FIG. 6 is a schematic diagram of a small hairpin shRNA. The U6 promoter directs the transcription of downstream small hairpin shRNA; comprises 23S 1 sense strand bases and 23S 1 antisense strand bases.
FIG. 7 shows the Western Blotting detection of the expression of PRV1 protein in A2780/Taxol cells after p L KO.1-PRV1-sh1 transfection.
FIG. 8 shows the change in the number and morphology of A2780/Taxol cells after transfection of p L KO.1-PRV1-sh1 by phase contrast microscopy.
FIG. 9 shows the proliferation of A2780/Taxol cells after transfection of p L KO.1-PRV1-sh1 by bromine labeling.
FIG. 10 shows the detection of Caspase3 activity on apoptosis of A2780/Taxol cells after transfection of p L KO.1-PRV1-sh 1.
FIG. 11 shows the migration ability of A2780/Taxol cells after transfection of p L KO.1-PRV1-sh1 in a cell scratch test.
FIG. 12 shows the migratory capacity (A) and the invasive capacity (B) of A2780/Taxol cells after transfection of p L KO.1-PRV1-sh1 by Transwell assay.
FIG. 13 shows the reversal of paclitaxel resistance in A2780/Taxol cells after transfection of p L KO.1-PRV1-sh 1.
Detailed Description
The present invention will be further described with reference to the following examples. The methods used in the following examples are intended to better understand the invention but are not intended to limit it. Unless otherwise specified, the experimental methods mentioned in the examples are all conventional methods, and the experimental materials used are all purchased from conventional reagents companies.
The SPSS 18.0 statistical analysis software is adopted, and the data of each sample are averaged to be +/-standard deviation
As shown, the differences between the two groups were measured by T Test (Independent-Sample T Test), and the differences between the groups were measured by One-Way analysis of variance (One-Way ANOVA), IC50Using probit regression analysis, P < 0.05 was statistically different.
Ovarian cancer cell strain A2780 and ovarian cancer Taxol resistant cell strain A2780/Taxol are preserved in a cell bank of a key laboratory of female reproductive health research in Zhejiang province;
mouse anti-human PRV1 primary antibody (Cat. sc-374291) was purchased from Santa Cruz, mouse anti-human GAPDH primary antibody (Cat.60004-1-Ig), horseradish peroxidase-labeled goat anti-mouse IgG (H + L) secondary antibody (Cat. SA00001-1) was purchased from Proteitech;
western Blotting L ulinol Reagent kit (Cat. sc-2048) was purchased from Santa Cruz;
cDNA reverse transcription kit PrimeScriptTMRT Master Mix (Cat. RR036A), fluorescent quantitative PCR assay kit SYBR Premix Ex Taq (perfect Real time, Cat. DRR041A) from TaKaRa company, L ipofectamine3000 transfection kit (Cat. L3000008) from Invitrogen company;
the eukaryotic expression vector selects an RNAi vector p L KO.1puro, which is derived from a global scientist plasmid sharing non-profit tissue Addgene;
restriction enzymes Age I (Cat. R0552S), EcoR I (Cat. R0101S), Kpn I (Cat. R0142S) were purchased from NEB; t4 ligase (Cat.2011A), a DNA fragment purification kit (Cat.9761), a DNA gel recovery kit (Cat.9762) and a plasmid DNA small purification kit (Cat.9760) are all purchased from TaKaRa company;
siRNA was synthesized by TaKaRa; PCR primers and DNA for cloning were synthesized by Shanghai Bioengineering Co., Ltd;
prestained protein Marker (cat.26616) available from Fermentas corporation;
bromine-labeling Cell Proliferation assay kit Cell Proliferation E L ISA, BrdU (colorimetric, cat.11647229001) was purchased from Roche;
CaspACE Assay System (colorimetric, Cat. G7351) available from Promega;
cell migration, invasion model Transwell Permeable Supports (Cat.3428) was purchased from Corning;
l ab-Tek II Chamber Slide System-L ab-Tek Chamber Slide System was purchased from Nunc corporation (Cat.154526);
BD MatrigelTMbasic Membrane matrix membranes (cat.356234) available from BD;
siRNA Negative Control AllStars Negative Control SiRNA (Cat.1027281) was purchased from QIAGEN;
SDS-PAGE gel preparation kit (cat. cw0022m) purchased from kazai century corporation;
0.45um PVDF membrane (Cat. IPVH00010) was purchased from Millipore;
paclitaxel (cat. P106868) was purchased from Aladdin.
Example 1 study of PRV1 expression differences in ovarian cancer cell line A2780 and paclitaxel-resistant cell line A2780/Taxol thereof
First, real-time fluorescent quantitative RT-PCR (qRT-PCR) is used for detecting PRV1 gene mRNA expression
After 48h incubation, the medium in the 6-well plate was aspirated, washed twice with PBS, and total RNA was extracted with Trizol, and the RNA concentration was determined with a ThermoNano Drop2000 spectrophotometer, according to the SYBR Premix Ex Taq (perfect reaction time) kit instructions. First step RNA denaturation, reaction system: RNA0.5ug, adding DEPC water to 6.8 ul; reaction conditions are as follows: incubate at 70 ℃ for 10min and place on ice. The second step of reverse transcription, reaction system: reverse transcription was performed according to PrimeScript RTMaster Mix kit instructions; reaction conditions are as follows: incubating at 42 deg.C for 60min, inactivating at 85 deg.C for 5min, and storing at-20 deg.C.
Taking 1ul of reverse transcription product to perform fluorescent quantitative PCR reaction. PCR primer sequences:
5’-GCCTGGAGTCTCTCACTTG-3’；
5'-CCCCAGTGTTGCTGTTAGGT-3', product length: 248 bp;
reaction conditions are as follows: 10s at 95 ℃, 5s at 95 ℃ and 30s at 6 ℃ for 40 cycles.
The expression level of PRV1mRNA in each group of samples was calculated by 2- △ CT method.
As a result: as shown in FIG. 1, PRV1mRNA expression was 89.58% higher in A2780/Taxol cells compared to its parent cell, A2780 (P < 0.05), indicating that PRV1mRNA expression was significantly higher in the paclitaxel-resistant cell line.
Second, Western Blotting detection of PRV1 protein expression
After 72H of culture, the culture medium in a 6-well plate is sucked away, PBS is washed for 3 times, RIPA protein lysate (100 ul/well) is added, the mixture is blown and beaten for several times, the mixture is incubated for 5min on ice to be fully cracked, the mixture is centrifuged for 5min at 4 ℃ and 12000 times, supernatant is collected and stored at 20 ℃ below zero, 10ul of sample is taken after 5min of denaturation at 95 ℃ of each sample, 8 percent SDS-PAGE electrophoresis is performed at 200V and 10min, 100V and 100min are performed, the mixture is transferred to PVDF membrane at 110V and 120min, 5 percent skim milk powder-containing TBS blocking solution is used for blocking for 60min, primary antibody incubation is performed at PRV1 primary antibody (1: 200), GAPDH primary antibody (1: 395000) for 2H at room temperature, TBS membrane washing is performed for 10min for 3 times, secondary antibody incubation is performed at 10min, goat anti-mouse IgG (H + L) IgG (1: 10000), horseradish peroxidase-goat anti-rabbit IgG (H + L) (1H), TBST 3 min, 10min, goat anti-mouse anti-rabbit IgG (H + 395925) is performed with Image washing by using a goat anti-TBGE (1: 10-TBS) and 10 min), and then Image scanning is performed on a goat anti-TBS.
As a result: as shown in FIG. 2, PRV1 protein expression was also significantly increased (P < 0.05) in A2780/Taxol cells compared to its parent cell, A2780.
Example 2 PRV1siRNA design Synthesis
Searching PRV1 gene mRNA sequence (NM-020406.3) in Genebank, using siDirect Ver2.0 software (http:// siDirect2.rnai.jp /) to design on line and obtain 3 pairs of siRNA sequences (as shown in SEQ ID NO.1-SEQ ID NO. 6). The sequence satisfying three algorithms reported in literature (Ui-Tei × Reynolds × Amarzguio) at the same time is selected in the design process, and 23nt length segment with highest siRNA action specificity is selected, the design can avoid the generation of interferon-like immunoreaction in vivo experiment, 100nt after the initial codon is selected, 5 ' and 3 ' end UTR region are avoided, GC content is controlled at 30-70%, the externally hung siRNA with 3 to 23nt length is selected as experiment screening interference segment, the structural feature is that the sense strand and the antisense strand have two bases at the 3 ' end, the structure is characterized as follows
Followed by B L ASTN(https://blast.ncbi.nlm.nih.gov/Blast.cgi)Homology search is carried out on line, sequences with homology are excluded, and the influence of nonspecific fragments on the specific action effect of siRNA is avoided as much as possible.
And finally, carrying out 2 '-OMe (2' -methoxyl) modification on 3 continuous purine (pyrimidine) bases at the 5 'end and the 3' end of the sense strand and the antisense strand during chemical synthesis, so that the chemical stability of the siRNA molecule in cells is increased, and the time and effect of siRNA interfering gene expression down regulation are prolonged. The final sequences and modifications are shown in Table 1 and formula (I) below:
TABLE 1
Example 3 detection and screening of interference Effect of three pairs of PRV1siRNA on PRV1 Gene in Taxol drug-resistant Strain A2780/Taxol for ovarian cancer
Firstly, experimental grouping:
A2780/Taxol normal group (no siRNA transfection), hereinafter referred to as AR;
A2780/Taxol negative control group (transfection negative control siRNA), hereinafter referred to as AR-N;
A2780/Taxol panel (transfection S1), hereinafter referred to as AR-S1;
A2780/Taxol panel (transfection S2), hereinafter referred to as AR-S2;
A2780/Taxol panel (transfection S3), hereinafter referred to as AR-S3.
Two, grouped transfection
To ensure transfection efficiency and reduce cytotoxicity, we used L ipofectamine3000 transfection reagent for siRNA transfection one day before transfection, cells were trypsinized and counted, and cells were plated in six-well plates to give a density of 0.5 × 10 on the day of transfection6The cells were fused to 70-90% by diluting 5ul L ipofectamine3000 reagent per well with 125. mu.l serum-free OPTI-MEM medium and mixing well, preparing siRNA premix, diluting siRNA to a final concentration of 50nM with 125. mu.l serum-free OPTI-MEM medium and mixing well, adding siRNA premix (1:1) to the diluted L ipofectamine3000 reagent, incubating at room temperature for 5min, adding siRNA-liposome complex to the cells, and CO at 37 ℃ and 5%2The culture is continued. PRV1mRNA expression was detected after 48h, and PRV1 protein expression was detected after 72 h.
Third, real-time fluorescent quantitative RT-PCR (qRT-PCR) is used for detecting PRV1 gene mRNA expression
The detection procedure was performed as before, and the expression level of PRV1mRNA in each group of samples was calculated by 2- △ CT method.
As a result: as shown in FIG. 3, after the A2780/Taxol cells are transfected with S1, S2 and S3 respectively, the expression of PRV1mRNA is obviously reduced, wherein the interference effect of S1 is compared with that of a negative control group, PRV1mRNA is down-regulated by 84.33%, and is significantly different (P is less than 0.05) compared with S2 (46.64%) and S3 (41.04%). The results show that S1 has the best interference effect on PRV 1.
Fourth, Western Blotting detection of PRV1 protein expression
Detection procedures As before, after EC L development, the images were scanned with Image Quant L AS4000mini (GE Healthcare).
As a result: as shown in FIG. 4, PRV1 protein expression was significantly reduced in A2780/Taxol cells after transfection with S1 (P < 0.05) compared to the negative control, and significantly different from S2 and S3 (P < 0.05). The results show that S1 has the best interference effect on protein expression of PRV1 in paclitaxel-resistant strain A2780/Taxol. Therefore, S1 was selected as siRNA for subsequent studies.
Example 4 construction of eukaryotic vector p L KO.1-PRV1-sh1 and detection of interference effect on PRV1 Gene expression
Firstly, experimental grouping:
A2780/Taxol normal group (without transfection of any vector), hereinafter referred to as AR;
A2780/Taxol negative control group (transfected p L KO.1puro empty vector), hereinafter referred to as AR-N;
A2780/Taxol panel 1 (transfection p L KO.1-PRV1-sh1), hereinafter referred to as AR-sh 1;
II, synthesis of PRV1-S1 fragment
Selecting two restriction sites of Age I and EcoR I, designing shRNA sequence according to the sequence of S1 and constructing into eukaryotic expression vector p L KO.1puro, wherein the sequence is as follows:
sense strand:
5’-CCGGTGTTCTTAGGGGTCCATTGCCGGTTCAAGAGACCGGCAATGGACCCCTAAGAACATTTTTTGGTACC-3’(SEQ ID NO.7)；
antisense strand:
5’-AATTGGTACCAAAAAATGTTCTTAGGGGTCCATTGCCGGTCTCTTGAACCGGCAATGGACCCCTAAGAACA-3’(SEQ ID NO.8)；
thirdly, construction of eukaryotic vector p L KO.1-PRV1-sh1
Eukaryotic expression vector p L KO.1puro was used to construct p L KO.1-PRV1-sh1 recombinant expression vector (FIGS. 5 and 6), which is described in molecular cloning, A.C. Cold spring harbor Press.
PRV1-S1 sense strand and antisense strand are annealed (denaturation at 95 ℃ for 2 min; slow cooling annealing to 25 ℃) and stored at 4 ℃, Age I and EcoR I completely digest the vector p L KO.1puro at 37 ℃ overnight, the digested product is recovered by a DNA gel recovery kit, DNA is recovered by the annealed product and the digested recovered fragment of the vector are subjected to ligation reaction, the reaction system (10ul) comprises 1ul of T4 ligase and 1ul of T4 ligase buffer, the mixture of the annealed product and the digested recovered fragment of the vector (molar ratio is 3:1), deionized water is supplemented to 10ul, ligation is performed overnight at 16 ℃, 5ul of the ligated product is placed in 100ul of JM109 competent bacteria, ice bath is performed for 30min, heat shock is performed at 42 ℃ for 90S, ice bath is performed for 5min, 1000ul of L B medium is added, incubation is performed for 30min at 37 ℃, centrifugation is performed for 5min at 5000rpm, supernatant is removed, the bacteria are evenly spread on L B plate (containing 50 ug/ml), penicillin is cultured at 37 ℃ for 1000ul, ampicillin is performed for 30min, a plurality of inverted culture medium containing penicillin, plasmid is performed overnight, plasmid containing bacterium is obtained, plasmid is inoculated in a colony amplification for overnight, plasmid is obtained, plasmid is subjected to obtain plasmid DNA, plasmid 8 ℃, plasmid is subjected to obtain plasmid purification, plasmid is subjected to shake culture, plasmid purification at 37.
Fourthly, observing interference effect after the p L KO.1-PRV1-sh1 recombinant plasmid transfects cells
P L KO.1-PRV1-sh1 was transfected into A2780/Taxol cells in logarithmic growth phase according to the L ipofectamine3000 instruction, each well was diluted with 125. mu.l of serum-free OPTI-MEM medium to 5. mu.l of L ipofectamine3000 reagent and mixed well, 5ug of recombinant plasmid DNA was added to 125. mu.l of serum-free OPTI-MEM medium, 10ul of P3000 reagent was added to prepare a recombinant plasmid premix, the diluted L ipofectamine3000 reagent was added to the recombinant plasmid premix (1:1), incubated at room temperature for 5 mm, and finally 250. mu.l of recombinant plasmid-liposome complex was added to the cells at 37 ℃ and 5% CO2The culture is continued. PRV1 protein expression was detected after 72 h.
As shown in figure 7, after the P L KO.1-PRV1-sh1 recombinant plasmid is transfected, compared with a negative control (transfection empty plasmid), the PRV1 protein expression in A2780/Taxol cells is remarkably reduced (P < 0.05), and the result shows that the P L KO.1-PRV1-sh1 recombinant plasmid can effectively interfere with the protein expression of PRV 1.
Example 5 Effect of transfection of p L KO.1-PRV1-sh1 on tumor cell proliferation, apoptosis, migration and invasion after specific blocking of PRV1 expression
Firstly, experimental grouping:
A2780/Taxol normal group (without transfection of any vector), hereinafter referred to as AR;
A2780/Taxol negative control group (transfected p L KO.1puro empty vector), hereinafter referred to as AR-N;
A2780/Taxol panel (transfection p L KO.1-PRV1-sh1), hereinafter referred to as AR-sh 1.
Two, grouped transfection
The transfection procedure was as before, and cells were cultured after transfection for detection of proliferation, apoptosis, migration and invasion of cells.
Third, cell proliferation assay
The cells are transfected into p L KO.1-PRV1-sh1 in a 96-well plate and then cultured for 72 hours, 10ul BrdU labeling Solution is added into each well until the final BrdU concentration is 10uM, the cells are incubated for 2 hours at 37 ℃, the BrdU labeling Solution is sucked off, 200ul FixDenat is added into each well, the cells are incubated for 30 minutes at 20 ℃, the FixDenat is sucked off, 100ul anti-BrdU-POD is added into each well, the cells are incubated for 90 minutes at 20 ℃, 200ul washing Solution is washed for 3 times in each well, 100 ul/well bottom Solution is added, the cells are incubated for 20 minutes at 20 ℃, the absorbance (A) is measured at the wavelength of 370nm (reference wavelength of 492nm), and the cell proliferation capacity is measured by the AExperimental group/AControl groupAnd (4) showing.
As shown in FIG. 8 and FIG. 9, after the cells A2780/Taxol are transfected with P L KO.1-PRV1-sh1, the number of the cells in the experimental group is reduced by observation under a phase-contrast microscope, and the cell proliferation results tested by a bromine standard method show that compared with a negative control, the cell proliferation capacity of the experimental group is reduced by 50.47%, and the significant difference (P < 0.05) shows that the tumor cell proliferation can be inhibited after the expression of the PRV1 is specifically blocked.
Fourthly, detecting apoptosis by Caspase3 activity
Cells were harvested 72h after transfection and lysate adjusted to 1 × 10 cell density8(ii)/ml, ice lysis for 15min, 15000g × 20min, and collection of supernatant Positive and negative control samples were prepared simultaneously according to CaspACE Assay System (colorimetric) instructions, and the concentrations of each histone determined and adjusted to be the same, Caspace Assay buffer32ul, DMSO2ul, 100nM DTT 10ul was added to each well of 96-well plate, and the volume of deionized water adjusted to be equal98ul, 2ul of DEVD-pNA substrate is added, incubation is carried out for 4h at 37 ℃, the absorbance is measured at the detection wavelength of 405nM, and the Caspase3 activity of each group of samples is calculated by the delta A method.
The results are shown in FIG. 10, after the A2780/Taxol cell is transfected with P L KO.1-PRV1-sh1, the activity of Caspase3 is increased by 2.92 times, and compared with a negative control, the significant difference (P is less than 0.05) is generated, which indicates that after the expression of PRV1 is specifically blocked, the tumor cell apoptosis can be promoted.
Fifth, cell migration ability test
Uniformly marking transverse lines on the back of a six-hole plate by using a ruler, marking one transverse line by about 0.5cm, crossing through holes, wherein each hole is provided with at least 6 transverse lines, after cell transfection is carried out on p L KO.1-PRV1-sh1, continuously culturing for 24h, and when the cells are fused into a single-layer state, vertically scratching the selected area in the six-hole plate by using a 200ul gun head, washing for 3 times by using PBS (phosphate buffer solution) to remove the marked cells, adding a serum-free culture medium to continuously culture, taking pictures at time points of 0h, 24h and 48h, randomly selecting 6 horizontal lines, and calculating the average value of the distances between the cells.
The result is shown in figure 11, after p L KO.1-PRV1-sh1 transfects cells for 24 hours and 48 hours, the distance between A2780/Taxol cells is obviously larger than that of a negative control group, the healing capacity of the cells after scratching is obviously reduced, and the result shows that the cells can inhibit the migration of tumor cells after the expression of PRV1 is specifically blocked.
Sixth, Transwell test for detecting cell migration ability
48h after cell transfection, the cells were collected by trypsinization, resuspended in serum-free medium and adjusted to a cell density of 5 × 105Adding 2ml of cell suspension into an upper chamber, adding 2ml of 10% FBS complete culture medium into a lower chamber, continuously culturing for 24h, taking out a small chamber, washing with PBS for 3 times, carefully removing cells on the surface of the upper layer of the upper chamber by using a cotton swab, inverting and airing, fixing with 95% ethanol for 25min, staining with hematoxylin, observing under a microscope, counting and taking a picture. 10 fields were counted per chamber, averaged and analyzed for changes in cell migration capacity.
The results of cell migration experiments are shown in FIG. 12A, the cell numbers of the A2780/Taxol experimental group and the negative control group penetrating the chamber after P L KO.1-PRV1-sh1 transfection are 76 + -21 and 301 + -42 respectively, and the two are statistically different (P < 0.05), and the results show that the tumor cell migration can be inhibited after the expression of PRV1 is specifically blocked.
Seventhly, cell invasion capacity detection by Transwell test
Liquefying matrigel stored at-20 deg.C at 4 deg.C, mixing matrigel with OPTI-MEM at a ratio of 1:6 ice, diluting, coating the upper surface of the bottom membrane of the chamber, solidifying at 37 deg.C for 30min, and removing the liquid separated out from the chamber. The remaining steps after matrigel coating were as above, 10 fields were counted per chamber, and changes in cell invasiveness were counted and analyzed by averaging.
The results of the cell invasion assay are shown in FIG. 12B, the numbers of cells penetrating the chamber of the A2780/Taxol test group and the negative control group are 42 + -17 and 203 + -39 respectively, and the two groups have statistical difference (P < 0.05); the results show that the tumor cell infiltration can be inhibited after the expression of PRV1 is specifically blocked.
Example 6 reversal of drug resistance to ovarian cancer after specific blockade of PRV1 expression by p L KO.1-PRV1-sh1
Firstly, experimental grouping:
a2780 normal group (without transfection of any vector), hereinafter referred to as a;
A2780/Taxol normal group (without transfection of any vector), hereinafter referred to as AR;
A2780/Taxol negative control group (transfected p L KO.1puro empty vector), hereinafter referred to as AR-N;
A2780/Taxol panel (transfection p L KO.1-PRV1-sh1), hereinafter referred to as AR-sh 1.
Two, grouped transfection
The transfection procedure was as before, and cells were cultured for 24h after transfection.
Thirdly, detecting the sensitivity of the cells to the paclitaxel after the p L KO.1-PRV1-sh1 transfection
Cells in logarithmic growth phase were taken from each group, cells were resuspended after trypsinization, cell counts and cell suspension density was adjusted to 1 × 105And/ml, inoculating into a 96-well plate and continuing culturing for 24 hours. The next day, paclitaxel is added into each group, the concentration gradient is respectively set at 200ug/ml, 100ug/ml, 50ug/ml, 25ug/ml, 12.5ug/ml, 6.25ug/ml, 3.125ug/ml and 0ug/ml, after 24h of action, absorbance (A) is measured at wavelength 370nm (reference wavelength 492nm) by bromine standard method, and Taxus cuspidata is calculatedInhibition rate of alcohol on each group of cells, inhibition rate being AExperimental group/ANegative control group.3 replicate wells were set for each concentration and the average was taken.
The drug concentration at 50% inhibition was half the Inhibitory Concentration (IC)50)；
IC of drug-resistant strain A2780/Taxol50IC with its parent cell line A278050The ratio of (A) to (B) is the Resistance Fold (RF);
IC of drug-resistant strain A2780/Taxol50IC with it after transfection of p L KO.1-PRV1-sh1 (Reversant)50The ratio of (A) to (B) is the resistance Reversal Index (RI).
The results are shown in Table 2, Table 3 and FIG. 13, IC of A2780/Taxol vs. paclitaxel50(35.89 + -5.27 ug/ml) was significantly higher than the IC of parent A2780 for paclitaxel50(1.26 +/-0.48 ug/ml) and the drug resistance times are as high as 28.48, which indicates that the sensitivity of A2780/Taxol to paclitaxel is obviously lower than that of a parent cell A2780 and the drug resistance is high, while the sensitivity of A2780/Taxol to paclitaxel is obviously improved (2.68 +/-0.71 ug/ml) after the A2780/Taxol transfects p L KO.1-PRV1-sh1, and the reversion effect of the transfected p L KO.1-PRV1-sh1 to the drug resistance of A2780/Taxol is very obvious, and the reversion index is 12.97.
TABLE 2 drug sensitivity of A2780 and A2780/Taxol to paclitaxel
TABLE 3 reversion of the drug sensitivity of A2780/Taxol to paclitaxel after transfection of p L KO.1-PRV1-sh1
SEQUENCE LISTING
<110> Zhejiang university
<120> siRNA for specifically inhibiting PRV1 gene expression, recombinant vector and application thereof
<130>
<160>8
<170>PatentIn version 3.3
<210>1
<211>21
<212>RNA
<213> Artificial sequence
<400>1
uucuuagggg uccauugccg g 21
<210>2
<211>21
<212>RNA
<213> Artificial sequence
<400>2
ggcaauggac cccuaagaac a 21
<210>3
<211>21
<212>RNA
<213> Artificial sequence
<400>3
uuugucccca ccaggguuga u 21
<210>4
<211>21
<212>RNA
<213> Artificial sequence
<400>4
caacccuggu ggggacaaaa g 21
<210>5
<211>21
<212>RNA
<213> Artificial sequence
<400>5
uuuuggugga cagcccaccu c 21
<210>6
<211>21
<212>RNA
<213> Artificial sequence
<400>6
ggugggcugu ccaccaaaau g 21
<210>7
<211>71
<212>DNA
<213> Artificial sequence
<400>7
ccggtgttct taggggtcca ttgccggttc aagagaccgg caatggaccc ctaagaacat 60
tttttggtac c 71
<210>8
<211>71
<212>DNA
<213> Artificial sequence
<400>8
aattggtacc aaaaaatgtt cttaggggtc cattgccggt ctcttgaacc ggcaatggac 60
ccctaagaac a 71
Claims (4)
1. The application of the siRNA for specifically inhibiting PRV1 gene expression in the preparation of the medicine for reversing the drug resistance of ovarian cancer taxol is characterized in that the siRNA comprises a sense strand and an antisense strand, wherein the nucleotide sequence of the sense strand is shown as SEQ ID NO.1, and the nucleotide sequence of the antisense strand is shown as SEQ ID NO. 2.
2. The use of claim 1, wherein 3 bases at the 5 ' and 3 ' ends of the sense and antisense strands are 2 ' -methoxy modified.
3. The application of a recombinant vector containing a DNA sequence of siRNA for specifically inhibiting PRV1 gene expression in the preparation of drugs for reversing drug resistance of ovarian cancer paclitaxel is characterized in that the siRNA comprises a sense strand and an antisense strand, wherein the nucleotide sequence of the sense strand is shown as SEQ ID NO.1, and the nucleotide sequence of the antisense strand is shown as SEQ ID NO. 2.
4. The use of claim 3, wherein 3 bases at the 5 ' and 3 ' ends of the sense and antisense strands are 2 ' -methoxy modified.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710624257.8A CN107541515B (en) | 2017-07-27 | 2017-07-27 | siRNA for specifically inhibiting PRV1 gene expression and recombinant vector and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710624257.8A CN107541515B (en) | 2017-07-27 | 2017-07-27 | siRNA for specifically inhibiting PRV1 gene expression and recombinant vector and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107541515A CN107541515A (en) | 2018-01-05 |
| CN107541515B true CN107541515B (en) | 2020-08-04 |
Family
ID=60971058
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710624257.8A Expired - Fee Related CN107541515B (en) | 2017-07-27 | 2017-07-27 | siRNA for specifically inhibiting PRV1 gene expression and recombinant vector and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107541515B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110123828B (en) * | 2018-02-09 | 2021-11-30 | 复旦大学附属金山医院 | Application of PRALR inhibitor in preparation of medicine for treating paclitaxel-resistant ovarian cancer |
-
2017
- 2017-07-27 CN CN201710624257.8A patent/CN107541515B/en not_active Expired - Fee Related
Non-Patent Citations (4)
| Title |
|---|
| A2780 human ovarian cancer cells with acquired paclitaxel resistance display cancer stem cell properties;XIAOFENG HAN et al;《ONCOLOGY LETTERS》;20131231;摘要 * |
| Extracellular Matrix Proteins Expression Profiling in Chemoresistant Variants of the A2780 Ovarian Cancer Cell Line;RadosBaw Januchowski et al;《BioMed Research International》;20140430;第1-9页 * |
| siRNA核糖分子化学修饰对RNAi功能的影响;武文斌;《生物技术通报》;20091231;第3节 * |
| 卵巢癌肿瘤干细胞及其标志物在卵巢癌诊疗中作用的研究进展;敬宏等;《中华妇幼临床医学杂志》;20170430;第13卷(第2期);摘要，第3节 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107541515A (en) | 2018-01-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ou et al. | Hypoxia-induced shedding of MICA and HIF1A-mediated immune escape of pancreatic cancer cells from NK cells: role of circ_0000977/miR-153 axis | |
| Xu et al. | Regulation of HOXA11-AS/miR-214-3p/EZH2 axis on the growth, migration and invasion of glioma cells | |
| Luan et al. | Long non-coding RNA HOTAIR acts as a competing endogenous RNA to promote malignant melanoma progression by sponging miR-152-3p | |
| Gong et al. | LncRNA HAND2‐AS1 represses cervical cancer progression by interaction with transcription factor E2F4 at the promoter of C16orf74 | |
| Du et al. | Long non-coding RNA MAGI2-AS3 inhibits breast cancer cell migration and invasion via sponging microRNA-374a | |
| Wei et al. | circHIPK3 promotes cell proliferation and migration of gastric cancer by sponging miR-107 and regulating BDNF expression | |
| Zhao et al. | The role of IFITM3 in the growth and migration of human glioma cells | |
| Guo et al. | Upregulation of long noncoding RNA TUG1 promotes bladder cancer cell proliferation, migration, and invasion by inhibiting miR-29c | |
| Zhang et al. | MALAT1 inhibits the Wnt/β-catenin signaling pathway in colon cancer cells and affects cell proliferation and apoptosis | |
| He et al. | LncRNA DLEU2 promotes cervical cancer cell proliferation by regulating cell cycle and NOTCH pathway | |
| Wang et al. | Overexpression of serine/threonine‑protein kinase-1 in pancreatic cancer tissue: Serine/threonine-protein kinase-1 knockdown increases the chemosensitivity of pancreatic cancer cells | |
| Wang et al. | Gankyrin promotes epithelial-mesenchymal transition and metastasis in NSCLC through forming a closed circle with IL-6/STAT3 and TGF-β/SMAD3 signaling pathway | |
| Chi et al. | WBSCR22 confers cell survival and predicts poor prognosis in glioma | |
| Ding et al. | Long non-coding RNA FOXO1 inhibits lung cancer cell growth through down-regulating PI3K/AKT signaling pathway | |
| Wang et al. | LncRNA LOC728196/miR-513c axis facilitates glioma carcinogenesis by targeting TCF7 | |
| Zhu et al. | Long noncoding RNA LINC00963 promotes CDC5L-mediated malignant progression in gastric cancer | |
| Fang et al. | Circular RNA hsa_circ_0000700 promotes cell proliferation and migration in Esophageal Squamous Cell Carcinoma by sponging miR-1229 | |
| Lei et al. | circTLK1 facilitates the proliferation and metastasis of renal cell carcinoma by regulating miR-495-3p/CBL axis | |
| Zhang et al. | circ_SMAD2 regulate colorectal cancer cells proliferation through targeting miR-1258/RPN2 signaling pathway | |
| CN107354157B (en) | siRNA for specifically inhibiting LAMB1 gene expression, recombinant vector and application thereof | |
| Wang et al. | Knockdown of NOB1 expression by RNAi inhibits cellular proliferation and migration in human gliomas | |
| CN107541515B (en) | siRNA for specifically inhibiting PRV1 gene expression and recombinant vector and application thereof | |
| CN107541514B (en) | siRNA for specifically inhibiting CO L12A 1 gene expression, recombinant vector and application thereof | |
| CN107164378B (en) | siRNA for specifically inhibiting SPIB gene expression and recombinant vector and application thereof | |
| Wu et al. | G‐quadruplex‐enhanced circular single‐stranded DNA (G4‐CSSD) adsorption of miRNA to inhibit colon cancer progression |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20200804 Termination date: 20210727 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |